Medical Care Technologies Inc (MDCE): good loading zone

Play Episode

5min

Proactive - Interviews for investors

Gaming Realms CEO on 2024 successes, Slingo growth and 2025 outlook

Gaming Realms PLC CEO Mark Segal takes Proactive's Stephen Gunnion through the company's strong 2024 financial performance and its ongoing international expansion. The company reported a year of strong growth, with revenue rising in both core content licensing and non-core social segments. Segal highlighted a “revenue increase, increase in our core content licensing business,” alongside gains in adjusted EBITDA and net profit, underlining operational leverage within the business. The company's flagship Slingo titles drove momentum, with 12 new releases in 2024 and North America contributing 54% of licensing revenue. “The cohorts of games we built in 2024 has probably been our highest-grossing sets of games in the first year,” said Segal. Gaming Realms is now live in five regulated U.S. states and recently launched in Brazil, aiming to deepen its presence in both. Segal also discussed the addition of third-party studio content, including Real Play, For The Player, and upcoming partner S Gaming, helping diversify offerings and penetrate high-barrier markets like the U.S. Cash generation remains strong, with a £13.5 million balance and a share buyback program underway. Looking ahead, Segal said the company expects continued organic growth, expansion into South Africa, and new launches with British Columbia’s lottery. Visit Proactive's YouTube channel for more investor-focused interviews. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss an update. #GamingRealms #Slingo #OnlineGaming #iGaming #GamingStocks #GamingInvestments #NorthAmericaGaming #BrazilGamingMarket #DigitalGames #InvestorUpdate #CashGenerative #LicensingRevenue #StockMarketNews

Proactive - Interviews for investors

Caledonia Mining sees big profit jump in 2024; welcomes gold's move above $3,000

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth talked with Proactive's Stephen Gunnion about the company’s strong 2024 financial performance and strategic priorities following the release of its latest results. Learmonth reported a “strong end to a reasonably good year,” with annual gold production reaching approximately 78,000 ounces—within guidance—supported by favourable pricing. He highlighted that “gross profit for the year was 77 million, compared to 41 million last year,” with adjusted earnings per share rising sharply from less than $0.10 in 2023 to nearly $1.30 in 2024. The results were delayed due to a technical accounting issue, with Learmonth explaining this stemmed from a deferred tax calculation error dating back to 2019. He stressed it had “no impact on our actual tax liabilities and tax payments.” On project development, the feasibility study for the Bilboes project has been extended to evaluate options that could significantly reduce capital costs. These include the potential to export concentrate and relocate the tailings facility, potentially lowering upfront investment needs. Exploration at both Blanket and Motapa returned positive results. Learmonth noted that the Blanket resource base has been extended, and early work at Motapa uncovered “exciting mineralisation” in new areas. With gold prices currently above $3,000 per ounce, the company is focused on maximising cash flow and investing further in Blanket and other revenue-generating opportunities. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #CaledoniaMining #GoldMining #MarkLearmonth #MiningStocks #GoldPrice #ZimbabweMining #BilboesProject #BlanketMine #MotapaExploration #InvestingInMining #MiningUpdate #ProactiveInvestors

Proactive - Interviews for investors

Nexus Minerals expands Payns Find gold target

Nexus Minerals Ltd managing director Andy Tudor talked with Proactive about the latest exploration success at the Payns Find gold target, part of the company's Wallbrook Gold Project in Western Australia. Tudor described the program as “exciting” following a third air core drilling campaign that confirmed high-grade intercepts and significantly expanded the mineralised footprint. He said, “All of the attributes for a big system are here,” highlighting consistent grades of up to 5.99g/t at the extremities of a 900m by 750m target zone. The air core results revealed both supergene and fresh rock mineralisation, with around 30% of the 163 holes showing elevated geochemistry in the final metre — a strong indicator of a large underlying system. “It’s that grade in the supergene and in the fresh rock that’s got us excited,” Tudor said. He also pointed to the presence of a full suite of alteration minerals — cerussite, rutile, tourmaline, and albite — typically associated with major gold systems in the region. With the air core phase now complete, Nexus is turning to reverse circulation (RC) drill planning. Tudor confirmed that air core drilling would continue regionally, while the company prepares for a comprehensive RC program at Payns Find to test depth extensions down to 120–150m. Visit Proactive's YouTube channel for more company interviews, and don’t forget to like this video, subscribe to the channel, and hit the notification bell for future updates. #NexusMinerals #GoldExploration #ASXStocks #WallbrookProject #PaynsFind #GoldMiningWA #RCDrilling #JuniorMiners #ASXNXM #MiningNews

Proactive - Interviews for investors

Solvonis Therapeutics engages PharmaVentures to support key AUD assets

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive about the company's strategic move to commercialise two clinical-stage assets targeting alcohol use disorder (AUD). Tennyson explained that Solvonis has engaged PharmaVentures to support valuation and potential out-licensing for two lead programs—AWKN-001 and AWKN-002. PharmaVentures was chosen based on its three-decade track record in biopharma M&A advisory, with over 1,000 deals completed. Tennyson noted, “We’ve selected them for three reasons: their expertise, their experience, and their reach.” The two assets originated from Solvonis's planned acquisition of Awakn Life Sciences, a transaction expected to be completed in the second quarter. AWKN-001, now in Phase 3 trials, targets severe AUD in the UK and EU. PharmaVentures estimates the asset could yield around £60 million in upfront and milestone payments, plus significant double-digit royalties. AWKN-002, focused on moderate to severe AUD in the US, is in Phase 2B planning. This program could generate approximately £150 million, based on comparable transactions. Tennyson emphasised the unmet medical need, citing a 75% relapse rate within a year for current AUD treatments. “That represents a significant commercial opportunity for Solvonis,” he said. For more interviews like this, visit Proactive's YouTube channel. Give this video a like, subscribe, and enable notifications to stay updated. #SolvonisTherapeutics #AlcoholUseDisorder #BiotechNews #ClinicalTrials #AWKN001 #AWKN002 #AddictionTreatment #PharmaVentures #MentalHealthInnovation #BiopharmaDeals #InvestorUpdate #HealthcareStocks #Phase3Trial #Outlicensing #Q2Milestones

Followers	43
Posts	22158
Boards Moderated	0
Alias Born	01/04/2011

Volume:	-
Day Range:
Bid:	0.0008
Ask:	0.0011
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

MDCE Detailed Quote

Recent MDCE News

More MDCE News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent MDCE News

Go Ad-Free